Medindia

X

Vista Partners Initiates Coverage on Helix BioPharma Corporation; Target Price $6.20

Wednesday, May 11, 2011 General News J E 4
Advertisement

SAN FRANCISCO, May 10, 2011 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Helix BioPharma Corporation (AMEX: HBP, TSX: HBP) ("the Company") with a twelve month target price of $6.20. Ross Silver, Principal Analyst at Vista Partners stated, "The Company is developing products for the treatment and prevention of cancer. The first and most advanced, Interferon alpha-2b, is a potent immuno-modulatory drug compound that has been formulated as a topical cream ("TIFNa2b") using Helix's unique, patented Biphasix™ platform technology which is intended to resolve low-grade cervical intraepithelial neoplasia grade 1 or 2 ("CIN 1 or 2") lesions. We believe TIFNa2b, if approved, could have revenues in excess of $500M globally, given the fact that the prospective market size is considerable, with approximately 1.3 million new cases of low-grade cervical lesions diagnosed annually each year in the U.S. alone today for which there are no approved pharmaceutical therapies." Mr. Silver concludes, "The Company's L-DOS47 is the first targeted therapeutic immunoconjugate under development based upon Helix's DOS47 technology. Helix's L-DOS47 is a new drug in development that is intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer ("NSCLC")."

To download a FREE copy of the Helix BioPharma Corporation research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. Vista Partners LLC is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.

Contact:877.215.4813 or info@vistapglobal.com

SOURCE Vista Partners

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
NYC Man with Alzheimer's Recovered Quickly, Safely...
S
Get In Shape For Women Hosts Spring Open House on ...